Related Experiment Video

Updated: Dec 23, 2025

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.8K

Immunomodulation by anticancer cell cycle inhibitors

Giulia Petroni1, Silvia C Formenti1,2, Selina Chen-Kiang2,3

  • 1Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.

Nature Reviews. Immunology
|April 30, 2020
PubMed

Insights

CDK4/6 inhibitors, like palbociclib, abemaciclib, and ribociclib, not only halt cancer cell cycle progression but also enhance the immune system. This dual action supports effective anti-tumor immunity, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cyclin-dependent kinase 4 and 6 (CDK4/6) are frequently dysregulated in cancers.
  • CDK4/6 inhibitors are emerging as targeted cancer therapies, with several approved for breast cancer.
  • These inhibitors are under investigation for various solid and hematological malignancies.

Purpose of the Study:

  • To review the mechanisms by which CDK4/6 inhibitors exert anticancer effects.
  • To highlight the immunostimulatory properties of CDK4/6 inhibitors.
  • To discuss the role of these inhibitors in modulating immune functions for enhanced anti-tumor immunity.

Main Methods:

  • Review of preclinical and clinical evidence.
  • Analysis of studies on cell cycle inhibition.
  • Evaluation of research on immune system modulation by CDK4/6 inhibitors.

Main Results:

  • CDK4/6 inhibitors effectively block cell cycle progression in malignant cells.
  • These inhibitors demonstrate significant immunostimulatory effects.
  • Modulation of immune functions contributes to the overall anti-tumor activity.

Conclusions:

  • CDK4/6 inhibitors possess dual mechanisms of action: cell cycle arrest and immune stimulation.
  • Their ability to enhance anti-tumor immunity broadens their therapeutic potential.
  • Further research into their immunomodulatory effects could optimize cancer treatment strategies.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.3K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Molecular Factors Affecting Cell Division01:27

Molecular Factors Affecting Cell Division

Several external and internal factors influence the initiation and inhibition of cell division. For instance, the death of nearby cells or the release of human growth hormone (hGH) promotes cell division. In contrast, lack of hGH or crowding of cells can inhibit cell division.
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K